Abstract
Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Current Enzyme Inhibition
Title: Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Volume: 7 Issue: 2
Author(s): Kalyan K. Sethi, Padilam Suresh and Sumanta Mondal
Affiliation:
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Abstract: Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Export Options
About this article
Cite this article as:
K. Sethi Kalyan, Suresh Padilam and Mondal Sumanta, Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius, Current Enzyme Inhibition 2011; 7(2) . https://dx.doi.org/10.2174/157340811796575272
DOI https://dx.doi.org/10.2174/157340811796575272 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of SPECT and MRI for Pre and Postoperative Evaluation of Childhood Moyamoya Disease: Case Report and Review of Literature
Current Medical Imaging Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry A Review on Possible Therapeutic Effect of Nigella sativa and Thymoquinone in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Interleukin-1β Plays a Role in the Activation of Peripheral Leukocytes after Blood-Brain Barrier Rupture in the Course of Subarachnoid Hemorrhage
Current Neurovascular Research Schiff Bases of Benzothiazol-2-ylamine and Thiazolo[5,4-b] pyridin-2-ylamine as Anticonvulsants: Synthesis, Characterization and Toxicity Profiling*
Central Nervous System Agents in Medicinal Chemistry Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Biochemical, Enzymatic and Molecular Properties of Renin/Prorenin Mediated by (Pro)Renin Receptor
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives
Current Neuropharmacology A Comprehensive Investigation of Molecular Signatures and Pathways Linking Alzheimer’s Disease and Epilepsy <i>via</i> Bioinformatic Approaches
Current Alzheimer Research Toward the Identification of Novel Carbonic Anhydrase XIV Inhibitors using 3D-QSAR Pharmacophore Model, Virtual Screening and Molecular Docking Study
Letters in Drug Design & Discovery How do Glial Cells Contribute to Motor Control?
Current Pharmaceutical Design Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Subject Index to Volume 1
Current Neurovascular Research